Latest Stories
3 Reasons to Sell PESI and 1 Stock to Buy Instead
Perma-Fix has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 10.8% to $11.25 per share while the index has gained 13.7%.
3 Reasons to Avoid EXPD and 1 Stock to Buy Instead
Expeditors’s 22.7% return over the past six months has outpaced the S&P 500 by 9%, and its stock price has climbed to $139.22 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
3 Reasons to Sell LFST and 1 Stock to Buy Instead
LifeStance Health Group trades at $6.18 per share and has stayed right on track with the overall market, gaining 8.9% over the last six months. At the same time, the S&P 500 has returned 13.7%.
BioMarin Pharmaceutical (BMRN): Buy, Sell, or Hold Post Q3 Earnings?
Over the past six months, BioMarin Pharmaceutical’s stock price fell to $51.76. Shareholders have lost 11.5% of their capital, which is disappointing considering the S&P 500 has climbed by 13.7%. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
3 Reasons LGIH is Risky and 1 Stock to Buy Instead
Over the past six months, LGI Homes’s stock price fell to $44.28. Shareholders have lost 15.8% of their capital, which is disappointing considering the S&P 500 has climbed by 13.7%. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
3 Reasons ACHC is Risky and 1 Stock to Buy Instead
Shareholders of Acadia Healthcare would probably like to forget the past six months even happened. The stock has dropped 39.1% and now trades at a new 52-week low of $14.31. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
3 Reasons AFG is Risky and 1 Stock to Buy Instead
American Financial Group trades at $137.11 and has moved in lockstep with the market. Its shares have returned 11.6% over the last six months while the S&P 500 has gained 13.7%.
3 Reasons to Avoid SNAP and 1 Stock to Buy Instead
Over the past six months, Snap’s shares (currently trading at $7.79) have posted a disappointing 6% loss, well below the S&P 500’s 13.7% gain. This may have investors wondering how to approach the situation.
MarketAxess (MKTX): Buy, Sell, or Hold Post Q3 Earnings?
MarketAxess’s stock price has taken a beating over the past six months, shedding 26.6% of its value and falling to $161.19 per share. This may have investors wondering how to approach the situation.
Charter (CHTR): Buy, Sell, or Hold Post Q3 Earnings?
Shareholders of Charter would probably like to forget the past six months even happened. The stock dropped 53.2% and now trades at $194.51. This was partly driven by its softer quarterly results and might have investors contemplating their next move.